Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth
Single-Dose Malaria Drug Moves To Phase II
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.
